The photo of the patient's foot, sent from his campsite, included a cheeky note: "I remember you telling me that getting in trouble doing something was better than getting in trouble doing nothing.

(Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases ...

The proportion of wounds healed at 16 weeks was higher with intact fish skin grafts than with standard-of-care (44.0% vs 26.4% adjusted odds ratio [aOR], 2.58; 95% CI, 1.48-4.56). The fish skin grafts ...

New England Journal of Medicine Evidence Publishes Results of the Largest Randomized Controlled Trial of its Kind ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis, the pioneer in the use ...

Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced it will present clinical application ...

Guest: Michelle Diss (Nurse Practitioner). HealthLine is a fast paced show that keeps you informed of the latest developments in the worlds of medicine, health and wellness. Since January of 1996, ...

Researchers have developed an experimental wound dressing for diabetic ulcers using biological material made by human cells, ...

Laboratory experiments exposed E. coli and MRSA to Nu-3 for 21 days. The minimum inhibitory concentration (MIC) changed in E.

Pemafibrate was tied to potential prevention of leg and foot ulcers in type 2 diabetes, a silver lining to the PROMINENT trial's otherwise disappointing cardiovascular results. In an exploratory ...

A recent ACS Pharmacology & Translational Science study examined the biogenic amines and small-molecule metabolites in diabetic foot ulcer (DFU) wound exudates to identify their potential roles in ...